Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
Resignation of Chief Financial Officer
On January 17, 2023, John P. Hamill, the Senior Vice President, Chief Financial
Officer and Corporate Secretary of Windtree Therapeutics, Inc. (the "Company")
notified the Company of his decision to resign effective as of January 27, 2023
(the "Effective Date"). Mr. Hamill resigned for personal reasons and not as a
result of any disagreement with the Company or its independent registered public
accountants on any matter relating to the Company's financial or accounting
operations, policies or practices.
Appointment of Interim Chief Financial Officer
On January 18, 2023, the board of directors of the Company appointed John
Tattory as Interim Chief Financial Officer, effective as of the Effective Date.
Mr. Tattory will also assume the duties of the principal financial officer and
principal accounting officer of the Company as of the Effective Date. Mr.
Tattory previously served as the Company's Senior Vice President and Chief
Financial Officer from March 2014 to July 2020. The Company intends to commence
a comprehensive search process to identify a new Chief Financial Officer.
Beginning January 19, 2023, Mr. Tattory will provide his services as a
consultant through LifeSci Associates ("LS Associates"), a business unit of
LifeSci Advisors, LLC, at an agreed upon hourly rate.
Mr. Tattory, age 57, is a Senior Consultant with LS Associates, a management
consulting firm, and has been associated with LS Associates since January 2023.
Prior to LS Associates, Mr. Tattory was the Chief Financial Officer of
Cerapedics, Inc., a commercial-stage ortho-biologics company, from September
2020 to December 2022. Mr. Tattory previously served as the Company's Senior
Vice President and Chief Financial Officer from March 2014 to July 2020, having
previously served as the Company's Vice President, Finance and Chief Accounting
Officer from March 2013 to March 2014, the Company's Vice President, Finance and
Controller and the designated principal accounting officer from July 2010 to
March 2013, and the Company's Vice President, Finance from January 2008 to July
2010. He brings more than 25 years of financial management and leadership
experience, including directing U.S. and international financial operations,
strategic transactions, licensing and collaboration arrangements, and equity and
debt financings. Prior to joining the Company, Mr. Tattory held financial
management positions at Tyco International and Bristol-Myers Squibb. Previously,
Mr. Tattory served as an Audit Manager with Ernst & Young LLP. Mr. Tattory is a
certified public accountant (currently inactive status) and holds a B.S. degree
in Commerce from Rider University.
There are no arrangements or understandings between Mr. Tattory and any other
persons pursuant to which Mr. Tattory was appointed as Interim Chief Financial
Officer of the Company. In addition, there are no family relationships
between Mr. Tattory and any director or executive officer of the Company, and
there are no transactions involving Mr. Tattory requiring disclosure under Item
404(a) of Regulation S-K.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses